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Abstract: The paper begins with a discussion of the needs and goals of metabolic predictions
in early drug research. Major difficulties toward this objective are examined, mainly the var-
ious substrate and product selectivities characteristic of drug metabolism. In a second part,
we classify and summarize the major in silico methods used to predict drug metabolism. A
discrimination is thus made between “local” and “global” systems. In the last part of the
paper, the program METEOR is presented and evaluated using the published metabolic data
of 10 substrates. 
DRUG METABOLISM AND THE MEDICINAL CHEMIST
Why are medicinal chemists concerned with drug metabolism?
Current “drug” discovery is mainly a ligand design aimed at discovering compounds with high affin-
ity/activity toward predefined biological targets. Modern high-throughput techniques have rendered this
strategy immensely successful, but much remains to be done to transform hits and ligands into well-be-
haved leads and clinical candidates. To decrease the costly and time-consuming development of active
compounds ultimately doomed by hidden pharmacokinetic or toxicological defects, medicinal chemists
now integrate metabolic considerations into drug design and lead optimization strategies [1]. As a re-
sult, many aspects of drug metabolism are of interest to medicinal chemists, including [2]:
• the chemistry and biochemistry of metabolic reactions; 
• the consequences of such reactions on activation and inactivation, toxification and detoxification;
• predictions of drug metabolism based on quantitative structure–metabolism relationships, expert
systems, and molecular modeling of enzymatic sites;
• prodrug and soft drug design; and 
• changes in physicochemical properties (acidity, basicity, lipophilicity, etc.) resulting from bio-
transformation.
Major reasons for the ever-increasing significance of biotransformation in drug discovery and de-
velopment are its frequent pharmacodynamic and pharmacokinetic consequences [2–4], as resulting
from the formation of:
• active metabolites from active drugs;
• active metabolites from prodrugs (activation);
• inactive metabolites (inactivation);
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• toxic metabolites (toxification), and particularly reactive metabolites able to form covalent
adducts with critical biomolecules;
• metabolites capable of inhibiting a metabolic pathway, producing complex kinetics; and
• metabolites having physicochemical properties vastly different from those of the parent com-
pound, for example, a very high lipophilicity resulting in tissue accumulation and residue reten-
tion.
These reasons have created a strong incentive for medicinal chemists to be able to anticipate the
biotransformation of any given compound, including the generation of reactive metabolites [5].
Whereas human expertise is irreplaceable, there is now a clear need for expert systems aimed at pro-
viding reliable and versatile metabolic predictions.
Goals of metabolic prediction
“Metabolic prediction” in itself is a fuzzy and broad concept which calls for definition and clarification.
A number of stepwise goals toward predicting the metabolism of a given compound are listed here [2]:
Goal 1. A list of all reasonable phase I and phase II metabolites
Goal 2. Same as above, organized in a metabolic tree
Goal 3. Same as above, plus a warning for reactive/adduct-forming metabolites
Goal 4. Same as above, plus (a) a probability of formation based on molecular factors, and (b) a fil-
ter against improbable metabolites
Goal 5. Same as above, plus a probability of formation under different biological conditions
Predicting all reasonable metabolites (Goal 1) represents the simplest goal. For want of a better
definition, we take “a reasonable metabolite” to be one that can be postulated on the grounds that the
substructural motif (functional group) undergoing the biotransformation has a precedent in the meta-
bolic chemistry literature, i.e., one not postulated solely on a mechanistic hypothesis. Classifying the
predicted metabolites into a metabolic tree (Goal 2) calls for additional rules, as does the identification
of potentially reactive and/or adduct-forming metabolites or metabolic intermediates (Goal 3). The dif-
ficulty reaches new heights when semi-quantitative predictions are sought, based on molecular proper-
ties of the substrate (Goal 4). The necessary rules must also originate in existing knowledge, but they
should be derived from structure–metabolism relationships using such statistical tools as multivariate
analyses and neural networks. The same is true for the highest level of difficulty, when biological fac-
tors are taken into account to modulate the predictions according to animal species, genetic factors, age,
etc. (Goal 5). In other words, the goal of the ultimate expert system would be to generate condition-de-
pendent, semi-quantitative metabolic trees, a goal that will only be met very progressively.
Challenge of substrate and product selectivities
There are a number of challenges to reliable drug metabolism prediction, foremost among which are the
many biological factors [2]:
• interindividual factors (i.e., which remain invariable for a given organism): animal species, ge-
netic factors, gender;
• intraindividual factors (i.e., which vary for a given organism): age, biological rhythms, disease,
stress, pregnancy, nutrition, influence of inducers and inhibitors.
Another major challenge in reliable prediction of metabolism, and one which deserves more in-
terest than it receives, arises from the various selectivities characteristic of metabolic processes.
Whereas there is only one type of selectivity at the receptor level, namely, the quantitatively or qualita-
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tively different responses elicited by various pharmacodynamic agents, two different types of selectiv-
ity exist in xenobiotic metabolism, namely, substrate selectivity and product selectivity (Table 1) [2,3].
Table 1 Types of selectivity seen in xenobiotic metabolism.
Substrate selectivity (broad sense) Product selectivity
Distinct substrates are metabolized: Distinct metabolites are produced:
• at different rates • from a single substrate
• under identical conditions • at different rates
• under identical conditions
Substrate selectivity (narrow sense) Chemoselectivity
(nonisomeric substrates) (chemically distinct reactions)
Substrate regioselectivity Product regioselectivity
(regioisomeric substrates) (regioisomeric products)
Substrate stereoselectivity Product stereoselectivity
(stereoisomeric substrates) (stereoisomeric products)
Substrate-product selectivities
Substrate selectivity is defined as the differential metabolism of distinct substrates under identi-
cal conditions; its analogy with pharmacodynamic processes is clear. In contrast, product selectivity
(defined as the differential formation of distinct metabolites from a single substrate under identical con-
ditions) has no known correspondence in receptor-mediated events. Both types of selectivity can be sub-
divided into subtypes depending whether substrates (or products) are nonisomeric (e.g., homologs,
analogs, or congeners), regioisomeric (i.e., positional isomers), or stereoisomeric (diastereomers or
enantiomers). These subtypes are listed and defined in Table 1. Product selectivity may also vary among
substrates, i.e., it may be substrate-selective (substrate-product selectivity).
Both substrate and product selectivity are of utmost significance when attempting to predict bio-
transformation. Indeed, substrate selectivity offers the conceptual framework to rank substrates accord-
ing to their relative rate of biotransformation by a given enzyme, in a given reaction, in a given organ,
in a given organism, etc. Product selectivity is even more important when a single substrate is consid-
ered, since it allows us to make sense of the relative rates of formation of metabolites generated by dif-
ferent routes, different enzymes, or even resulting from attack by the same enzyme at different positions
in the molecule. Thus, chemoselectivity will be observed when different types of atoms are attacked
(e.g., of O- vs. N-glucuronidation, N- vs. S-oxygenation, Csp3 vs. Csp2 hydroxylation), whereas regio-
selectivity implies that the same type of atom exists in the two or more positions being attacked (e.g.,
ortho- vs. para-hydroxylation). There is even some overlap between chemoselectivity and regio-
selectivity, e.g., phenol vs. alcohol glucuronidation, the chemical difference between the ether glu-
curonides so formed being small.
IN SILICO SYSTEMS TO PREDICT METABOLISM
In a schematic manner (Table 2), one can distinguish between two types of algorithms to predict drug
and xenobiotic metabolism [2], namely, “local” systems and “global” systems.
“Local” systems
“Local” systems apply to single enzymes or to single metabolic reactions, and they are usually restricted
to rather narrow chemical series. Such systems include quantitative structure–metabolism relationships
(QSMRs) based on structural and physicochemical properties [6]. Quantum mechanical calculations
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may also shed light on SMRs, revealing correlations between rates of metabolic oxidation and energy
barrier in cleavage of the target C−H bond [7]. Three-dimensional QSMRs (3D-QSMRs) methods yield
a partial view of the binding/catalytic site of a given enzyme as derived from the 3D molecular fields
of a series of substrates or inhibitors (the training set). In other words, they yield a “photographic neg-
ative” of such sites, and will allow a quantitative prediction for novel compounds structurally related to
the training set [8]. Two popular methods in 3D-QSARs are CoMFA (comparative molecular field
analysis) and Catalyst.
Table 2 A classification of in silico methods to predict biotransformation.
(A) “Local” methods
Applicable to simple biological systems (single enzyme, single reaction, ...)
and/or to series of compounds with “narrow” chemical diversity.
• QSAR (linear, multilinear, multivariate, …)
⇒ affinities, relative rates, …
(depending on the physicochemical properties considered)
• 3D-QSAR (CoMFA, Catalyst, GRID/GOLPE, …) 
⇒ substrate behavior, relative rates, inhibitor behavior, …
• Molecular modeling and docking
⇒ ligand yes/no (substrate? inhibitor?), regioselectivity, …
• Quantum mechanical (MO) methods (ab initio, semi-empirical)
⇒ regioselectivity, mechanisms, relative rates, …
(B)  “Global” methods
Applicable to versatile biological systems (many enzymes, many reactions, ...)
and/or to series of compounds with “broad” chemical diversity.
• Databases (MDL Metabolite Database, Biotransformations, ...)
⇒ nature of metabolites, reactive/adduct-forming metabolites, …
• Expert systems and their databases (META, MetabolExpert, METEOR,...)
⇒ nature of major and minor metabolites, metabolic trees, reactive/adduct-forming
metabolites, relative importance of these metabolites depending on biological
factors, …  
The molecular modeling of xenobiotic-metabolizing enzymes affords another approach to ration-
alize and predict drug–enzyme interactions [9]. Its application to drug metabolism was made possible
by the crystallization and X-ray structural determination of cytochromes P450. Given the assumptions
made in homology modeling and the lack of accurate scoring functions, such pharmacophoric models
cannot give quantitative affinity predictions. However, they can afford fairly reliable yes/no answers as
to the affinity of test set compounds, and even the regioselectivity of metabolic attack [10].
The pharmacophoric models of a large number of mammalian and mostly human CYPs are now
available, as well as other xenobiotic-metabolizing enzymes such as DT-diaphorase and glutathione
S-transferases. The crystallization and X-ray structural elucidation of mammalian cytochromes P450
[11,12] is a breakthrough that removes the set of assumptions inherent in homology modeling and will
thus improve the predictive power of molecular modeling.
Quantum mechanical methods are also classified as local in Table 2. Here, a word of caution is
necessary, since such methods are in principle applicable to any chemical system. However, they can-
not handle more than one metabolic reaction or catalytic mechanism at a time, and as such can only pre-
dict metabolism in simple biological systems, in contrast to the global methods presented in the next
subsection.
B. TESTA et al.
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“Global” systems
As reviewed by Hawkins [13], one approach to predict metabolism is to use databases in the form of
either knowledge-based systems or predictive expert systems. Existing knowledge-based systems [14]
include the MDL Metabolite Database [15], and the book series Biotransformations [16], which has
been produced as a software product called Metabolism [17]. These databases can be searched to re-
trieve information on the known metabolism of compounds with similar structures or containing spe-
cific moieties.
Predictive databases attempt to portray the metabolites of a compound based on knowledge rules,
defining the most likely products. Existing systems of this type are MetabolExpert [18], META [19],
and METEOR [20].
METEOR: A GLOBAL SYSTEM TO PREDICT METABOLISM
A brief presentation of METEOR
METEOR is a computer system which uses a knowledge base of structure–metabolism rules (biotrans-
formations) to predict the metabolic fate of a query chemical structure [21]. METEOR’s biotransfor-
mation rules are generic reaction descriptors rather than simple entries in a reaction database. The sys-
tem uses a rich internal structure representation language [22]. The expression of specific functional
group transformations can, therefore, be made context-sensitive.
Unconstrained analyses of query structures can give rise to a combinatorial explosion of results
data. To overcome this problem, METEOR has an integrated reasoning engine, based on a system of
non-numerical argumentation [23,24], which uses a repository of higher-level reasoning rules. The rea-
soning model built into METEOR allows the system to evaluate the likelihood of a biotransformation
taking place. METEOR is provided with a link to an external log P calculation program (Clog P [25]).
The likelihood of biotransformation can modified by the reasoning engine according to the general,
global relationship between lipophilicity and drug metabolism [6]. The system can also make compar-
isons between potentially competing biotransformations [26]. The user of the system can choose to an-
alyze queries at a number of available search levels. At high levels, only the more likely biotransfor-
mations are requested for display. At lower levels, the more putative metabolites are also selected for
display.
Input into the system is by graphical means or by molfile import. Output from the system is also
flexible. Results can be viewed from within the program where individual metabolites can be selected
and processed to deeper levels or sent to DEREK for Windows [27] for a toxicological assessment. The
metabolic tree can be searched by molecular mass, molecular formula, or structure. Reports can be gen-
erated in rich text format, and metabolites can be exported in SDfile format.
The system is also supplied with a knowledge base editor so that users can build their own bio-
transformations and rules. The predictive capability of the system is constantly being evaluated, and the
knowledge base and rule base are continuously being developed and improved.
An evaluation of METEOR
We have recently completed an evaluation study of the now outdated version 6.0 of METEOR, com-
paring its predictions (“retrodictions” or “retrospective results” would be more appropriate here) with
the published fate of nine drugs and one industrial chemical. Criteria for the selection of these 10 sub-
strates were impeccable biological data available from the literature, the chemical diversity of the sub-
strates, and extensive metabolism with multiple pathways. The 10 substrates were acenocoumarol, di-
clofenac, esonarimod, etoperidone, galantamine, gemifloxacine, n-hexane, indinavir, omapatrilat, and
tramadol.
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The results for acenocoumarol are summarized in Figs. 1A and 1B. There was a full qualitative
agreement between experiment and algorithm for seven reactions (Fig. 1A), five of which are clearly
mediated by cytochromes P450. Three reactions were predicted, but not seen (false positives).
Reactions mA8 and mA9 are reasonable ones which may have escaped experimental detection due to
low levels. In contrast, hydrolytic ring opening of functionalized coumarins (mA10) is poorly docu-
mented if at all [4], suggesting that additional structural constraints need to be implemented in the soft-
ware. Cytochrome P450-mediated reactions of dehydrogenation are rare, but greatly facilitated for
highly delocalized metabolites [3], as is the case here (eA11). This false negative offers a valuable ex-
ample of how an evaluation can help update the biotransformation dictionary of global systems.
For the 10 substrates, 130 first-generation metabolites were predicted and/or seen experimentally.
Correct predictions represented 30 % of these reactions, apparently false positives 62 %, and false neg-
atives 8 %. These 70 % discrepant results could be subdivided into 20 % apparently false positives due
to molecular constraints not being taken into account, 3 % false negatives due to missing reactions in
the biotransformation dictionary, and 47 % most probably due to the complexity of biological factors.
As stated, such results are of considerable interest in improving and updating the algorithm.
B. TESTA et al.
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Fig. 1A Metabolic scheme of acenocoumarol, comparing the experimental results [28] with the predictions of
METEOR version 6.0 [20]. (A) Metabolic reactions predicted and seen experimentally. (B) False positives
(predicted but not seen experimentally) and false negative (seen but not predicted).
CONCLUSION
Drug metabolism, like any other biological response, is heavily dependent on the molecular properties
of substrates. And this is an encouraging statement, since it implies that structure–metabolism relation-
ships do exist and hence that predictions are possible. Indeed, many local predictions have been re-
ported. These usually allow useful predictions within the explored space of molecular diversity and
property.
Global predictions are much more ambitious and, therefore, remain a greater challenge. Of
course, current expert systems will offer qualitative predictions as to possible metabolites, but the dan-
ger of false positives and false negatives is ever present. This is due to the complexity of molecular
structure, the diversity of modes of interactions between substrates and metabolizing systems, and,
above all, the many biological factors involved. And if one general conclusion should emerge from all
what biologists have learned about biological regulations, it is that biological factors are interdepend-
ent in a nonlinear manner. In other words, these factors not only influence the biological responses,
they also influence each other. The implication is that the systematic study of biological factors taken
one by one or few by few will never yield a complete understanding of biological regulations.
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Fig. 1B Metabolic scheme of acenocoumarol, comparing the experimental results [28] with the predictions of
METEOR version 6.0 [20]. False positives (predicted but not seen experimentally) and false negative (seen but not
predicted).
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